This study supports previous studies in suggesting that a PRS for overall prostate cancer can be used to provide a robust risk stratification of prostate cancer mortality.5,6 Although PSA levels may provide good short-term risk stratification,29,30 the advantage of the PRS is that it can be measured before any cancer starts to develop. This evidence concerns the gene KLK3 and cancer.